SCHEMBL3404599

SCHEMBL3404599

C=C(CCCOC(=O)CCCCCO)C(=O)O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DGKA P23743 1/20 0.43
GPR84 Q9NQS5 1/20 0.41
FFAR1 O14842 1/20 0.41
FFAR4 Q5NUL3 1/20 0.41
FNTA P49354 1/20 0.37
FNTB P49356 1/20 0.37
DNM1 Q05193 1/20 0.37
PAM P19021 2/20 0.36
TBXAS1 P24557 2/20 0.36
PRSS1 P07477 1/20 0.36
PRSS2 P07478 1/20 0.36
PRSS3 P35030 1/20 0.36
GAA P10253 1/20 0.34
TSHR P16473 1/20 0.34
ACHE P22303 2/20 0.33
MGLL Q99685 1/20 0.33
KDM4E B2RXH2 1/20 0.33
DUSP3 P51452 1/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2121930 0.91 DGKA (0.44) DGKAGPR84FFAR1FFAR4FNTA
SCHEMBL5504718 0.84 GPR84 (0.38) GPR84FFAR1FFAR4FNTAFNTB
SCHEMBL10708066 0.84 MGLL (0.41) DGKADNM1PAMTBXAS1TSHR
SCHEMBL139573 0.83 GPR84 (0.56) GPR84FFAR1FFAR4FNTAFNTB
SCHEMBL890450 0.83 GPR84 (0.56) GPR84FFAR1FFAR4FNTAFNTB
SCHEMBL3682582 0.83 GPR84 (0.56) GPR84FFAR1FFAR4FNTAFNTB
SCHEMBL743707 0.83 GPR84 (0.56) GPR84FFAR1FFAR4FNTAFNTB
SCHEMBL17240331 0.83 GPR84 (0.56) GPR84FFAR1FFAR4FNTAFNTB
SCHEMBL136691 0.83 GPR84 (0.56) GPR84FFAR1FFAR4FNTAFNTB
SCHEMBL157090 0.83 GPR84 (0.56) GPR84FFAR1FFAR4FNTAFNTB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2776008-B1 SURFACE TREATMENT COMPOSITIONS INCLUDING SHIELDING SALTS PROCTER & GAMBLE (US) 2017-02-15 EP claimed
EP-2776008-B1 SURFACE TREATMENT COMPOSITIONS INCLUDING SHIELDING SALTS PROCTER & GAMBLE (US) 2017-02-15 EP disclosed
US-8399569-B2 Reactive urethane compound having ether bond, curable composition, and cured material SHOWA DENKO K.K. (JP) 2013-03-19 US disclosed
US-20100160557-A1 REACTIVE URETHANE COMPOUND HAVING ETHER BOND, CURABLE COMPOSITION, AND CURED MATERIAL SHOWA DENKO K.K. (JP) 2010-06-24 US disclosed
US-7579066-B2 Ethylenically unsaturated group-containing isocyanate compound and process for producing the same, and reactive monomer, reactive (meth) acrylate polymer and its use SHOWA DENKO K.K. (JP) 2009-08-25 US disclosed
US-20070218305-A1 Photosensitive Resin Composition, Cured Product Thereof and Production Method of Printed Circuit Board Using the Same SHOWA DENKO K.K. (JP) 2007-09-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100160557-A1 REACTIVE URETHANE COMPOUND HAVING ETHER BOND, CURABLE COMPOSITION, AND CURED MATERIAL UNC119, MLLT1, H1-0 DGKA 3836/4885GPR84 1507/4885FFAR1 248/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.